• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    SC 13G/A 1 y1113240sc13ga3.htm AMENDMENT NO. 3
     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    IceCure Medical Ltd.
    (Name of Issuer)
     
     
    Ordinary Shares, no par value
    (Title of Class of Securities)
     
     
    M53071136
    (CUSIP Number)
     
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      
     

     

    CUSIP No. M53071136 13G/A Page 2 of 6 Pages

     

    1. NAMES OF REPORTING PERSON

    Epoch Partner Investments Limited
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ¨

    (b) ¨

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    British Virgin Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER
     

    25,846,597

    6. SHARED VOTING POWER
     
    0
    7.

    SOLE DISPOSITIVE POWER
     

    25,846,597

    8. SHARED DISPOSITIVE POWER
     
    0
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    25,846,597

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    52.2%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    CO

     

      (1) Percentage is based on the 49,517,660 Ordinary Shares of the Issuer that were outstanding as of June 30, 2024, based on information contained in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer on August 20, 2024.

     

      
     

     

    CUSIP No. M53071136 13G/A Page 3 of 6 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

    IceCure Medical Ltd. (the “Issuer”)

       
    (b)

    Address of Issuer’s Principal Executive Offices
    7 Ha’Eshel Street, P.O. Box 3163

    Caesarea 3079504, Israel

     

    Item 2.

     

    (a)

    Name of Person Filing:

     

    This Statement is filed by Epoch Partner Investments Limited

     

    The foregoing is referred to as the “Reporting Person” in this Statement.

       
    (b)

    Address of Principal Business Office or, if None, Residence:

     

    Epoch Partner Investments Limited

    Suite 7013, 2 International Finance Centre, 70/F, 8 Finance Street, Central, Hong Kong

       
    (c)

    Place of Organization:


    British Virgin Islands.

       
    (d) Title of Class of Securities
    Ordinary shares, no par value per share (“Ordinary Shares”)
       
    (e) CUSIP Number
    M53071136

     

      
     

     

    CUSIP No. M53071136 13G/A Page 4 of 6 Pages

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

    Item 4. Ownership.

     

    See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person. 

     

    Not applicable.

     

     

      
     

     

    CUSIP No. M53071136 13G/A Page 5 of 6 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. 

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

      

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

      
     

     

    CUSIP No. M53071136 13G/A Page 6 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    EPOCH PARTNER INVESTMENTS LIMITED

     

    By: /s/ Li Haixiang  
    Name: Li Haixiang  
    Date: November 14, 2024  

     

     

     

     

     

     

    Get the next $ICCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

      CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is

      5/21/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

      Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Papers of 2024" Cryoablation was mentioned favorably during the ASBrS Presidential Address CAESAREA, Israel, May 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas. "We co

      5/6/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

      Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study planIceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedureU.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to l

      4/30/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    See more
    • IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

      Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

      8/28/23 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

      Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

      12/6/22 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

      CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie

      11/29/21 1:07:00 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    SEC Filings

    See more
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      5/21/25 8:30:13 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      5/15/25 4:45:52 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13D filed by IceCure Medical Ltd.

      SCHEDULE 13D - IceCure Medical Ltd. (0001584371) (Subject)

      5/14/25 5:27:44 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on Icecure Medical with a new price target

      Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

      2/2/22 11:13:08 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on Icecure Medical with a new price target

      Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

      9/22/21 8:10:09 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Financials

    Live finance-specific insights

    See more
    • IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

      CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is

      5/21/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

      Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

      3/27/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

      CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Thursday, March 27, 2025, at 10:00 am EDTUS: 1-888-4

      3/21/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      11/14/24 9:38:43 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      2/14/23 8:46:31 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      1/24/23 5:04:22 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care